Companies › Elpida Therapeutics SPC
2 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Neurology; next expected readout Oct 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MELPIDA Recombinant adeno-associated virus serotype 9 (AAV9) encoding codon-optimized human AP4M1 | AP4M1 | Phase 3 | Hereditary Spastic Paraplegia Type 50; Spasticity, Muscle; Spastic Paraplegia Type 50 | Oct 2028 |
| ELP-02 AAV9-based gene therapy expressing FIG4 | FIG4 | Phase 1 | Charcot-Marie-Tooth Disease Type 4J | Dec 2032 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06069687 | MELPIDA | Phase 1 | Spastic Paraplegia Type 50 | Neurology | Mar 2027 |
| NCT05518188 | MELPIDA | Phase 1 | Spasticity, Muscle | Neurology | Oct 2028 |
| NCT06692712 | MELPIDA | Phase 3 | Hereditary Spastic Paraplegia Type 50 | Neurology | Feb 2032 |
| NCT07447557 | ELP-02 | Phase 1 | Charcot-Marie-Tooth Disease Type 4J | Neurology | Dec 2032 |
Alasht Pharmed MED Institute Sound Wave Innovation Dyne Therapeutics Navamedic
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.